{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:58:13Z","timestamp":1768294693453,"version":"3.49.0"},"reference-count":36,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"RCN","award":["312693"],"award-info":[{"award-number":["312693"]}]},{"DOI":"10.13039\/100031365","name":"Oslo University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KG Jebsen Foundation"},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation"},{"name":"Karin Fossum Foundation"},{"name":"Diakonhjemmet Hospital"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,9,28]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMID) following two vaccine doses. To protect these vulnerable patients against severe COVID-19 disease, a three-dose primary vaccination strategy has been implemented in many countries. The aim of this study was to evaluate humoral response and safety of primary vaccination with three doses in patients with IMID.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with IMID on immunosuppressive therapy and healthy controls receiving three-dose and two-dose primary SARS-CoV-2 vaccination, respectively, were included in this prospective observational cohort study. Anti-Spike antibodies were assessed 2\u20134 weeks, and 12 weeks following each dose. The main outcome was anti-Spike antibody levels 2\u20134 weeks following three doses in patients with IMID and two doses in controls. Additional outcomes were the antibody decline rate and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1100 patients and 303 controls were included. Following three-dose vaccination, patients achieved median (IQR) antibody levels of 5720 BAU\/mL (2138\u20138732) compared with 4495 (1591\u20136639) in controls receiving two doses, p=0.27. Anti-Spike antibody levels increased with median 1932 BAU\/mL (IQR 150\u20134978) after the third dose. The interval between the vaccine doses and vaccination with mRNA-1273 or a combination of vaccines were associated with antibody levels following the third dose. Antibody levels had a slower decline-rate following the third than the second vaccine dose, p&lt;0.001. Adverse events were reported by 464 (47%) patients and by 196 (78%) controls. Disease flares were reported by 70 (7%) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study shows that additional vaccine doses to patients with IMID contribute to strong and sustained immune-responses comparable to healthy persons vaccinated twice, and supports repeated vaccination of patients with IMID.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04798625\">NCT04798625<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002417","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T11:12:46Z","timestamp":1667473966000},"page":"e002417","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04798625","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04798625","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-3696","authenticated-orcid":false,"given":"Silje Watterdal","family":"Syversen","sequence":"first","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-9713","authenticated-orcid":false,"given":"Ingrid","family":"Jyssum","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-9835","authenticated-orcid":false,"given":"Anne Therese","family":"Tveter","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8429-8152","authenticated-orcid":false,"given":"Ingrid Egeland","family":"Christensen","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trung T","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-6760","authenticated-orcid":false,"given":"Kristin Hammersb\u00f8en","family":"Bj\u00f8rlykke","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"Mjaaland","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adity","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grete Birkeland","family":"Kro","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorgen","family":"Jahnsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludvig A","family":"Munthe","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"},{"name":"KG Jebsen Centre for B cell Malignancies, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-4745","authenticated-orcid":false,"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnveig","family":"Gr\u00f8deland","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Torgils","family":"Vaage","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8506-725X","authenticated-orcid":false,"given":"Guro L\u00f8vik","family":"Goll","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2025090313452083000_8.2.e002417.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025090313452083000_8.2.e002417.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025090313452083000_8.2.e002417.3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2025090313452083000_8.2.e002417.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2025090313452083000_8.2.e002417.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927"},{"key":"2025090313452083000_8.2.e002417.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3685"},{"key":"2025090313452083000_8.2.e002417.7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/art.42153","article-title":"Immunogenicity and safety of standard and Third-Dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy","volume":"74","author":"Syversen","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313452083000_8.2.e002417.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909094"},{"key":"2025090313452083000_8.2.e002417.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes305"},{"key":"2025090313452083000_8.2.e002417.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.023"},{"key":"2025090313452083000_8.2.e002417.11","doi-asserted-by":"crossref","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","article-title":"Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark","volume":"60","author":"Cordtz","year":"2021","journal-title":"Rheumatology"},{"key":"2025090313452083000_8.2.e002417.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322539"},{"key":"2025090313452083000_8.2.e002417.13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41575-021-00420-w","article-title":"SARS-CoV-2 vaccination in IBD: more pros than cons","volume":"18","author":"D'Amico","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025090313452083000_8.2.e002417.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02310-7","article-title":"Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases","volume":"20","author":"Wieske","year":"2022","journal-title":"BMC Med"},{"key":"2025090313452083000_8.2.e002417.15","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025090313452083000_8.2.e002417.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114583"},{"key":"2025090313452083000_8.2.e002417.17","doi-asserted-by":"publisher","DOI":"10.1016\/S01406736(21)01642-1"},{"key":"2025090313452083000_8.2.e002417.18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"The Lancet"},{"key":"2025090313452083000_8.2.e002417.19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"2025090313452083000_8.2.e002417.20","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104a2"},{"key":"2025090313452083000_8.2.e002417.21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3"},{"key":"2025090313452083000_8.2.e002417.22","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090313452083000_8.2.e002417.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221554"},{"key":"2025090313452083000_8.2.e002417.24","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2665-9913(21)00328-3","article-title":"Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses","volume":"4","author":"Schmiedeberg","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090313452083000_8.2.e002417.25","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090313452083000_8.2.e002417.26","doi-asserted-by":"crossref","unstructured":"Tran TT , Vaage EB , Mehta A . Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera. bioRxiv 2022:2022.2003.2026.484261.","DOI":"10.21203\/rs.3.rs-1500697\/v1"},{"key":"2025090313452083000_8.2.e002417.27","unstructured":"Norwegian immunisation registry (SYSVAK). Available: https:\/\/www.fhi.no\/en\/hn\/health-registries\/norwegian-immunisation-registry-sysvak\/"},{"key":"2025090313452083000_8.2.e002417.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"2025090313452083000_8.2.e002417.29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090313452083000_8.2.e002417.30","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1016\/S2665-9913(22)00191-6","article-title":"Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study","volume":"4","author":"Simon","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090313452083000_8.2.e002417.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02587-8","article-title":"The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study","volume":"20","author":"Christensen","year":"2022","journal-title":"BMC Med"},{"key":"2025090313452083000_8.2.e002417.32","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"2025090313452083000_8.2.e002417.33","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","article-title":"Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses","volume":"23","author":"Hall","year":"2022","journal-title":"Nat Immunol"},{"key":"2025090313452083000_8.2.e002417.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"2025090313452083000_8.2.e002417.35","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001342"},{"key":"2025090313452083000_8.2.e002417.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108480"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:45:31Z","timestamp":1756932331000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/rmdopen-2022-002417"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002417","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}